TABLE 1.

Risk‐stratified surveillance recommendations for HB in BWSp based on molecular subgroups.

	HB screening	Hepatic ultrasound a and duration	AFP screening
(Brioude et al., 2018)
BWS w/o molecular evidence	No	No	No
ICR‐1	No	No	No
ICR‐2	No	No	No
11p15 pUPD	Yes	Every 3 months till 7 yrs	No
CDKN1C‐mutation	No	No	No
(Maas et al., 2016)
BWS w/o molecular evidence	Yes	Every 3 months till 4 yrs	No
ICR‐1	No	No	No
ICR‐2	No	No	No
11p15 pUPD	Yes	Every 3 months till 4 yrs	No
CDKN1C‐mutation	facultative	Every 3 months till 4 yrs	No
(Mussa, Molinatto, et al., 2016)
BWS w/o molecular evidence	Not mentioned	Not mentioned	Not mentioned
ICR‐1	No	No	No
ICR‐2	No	No	No
11p15 pUPD	Yes	Every 3 months till 5 yrs	Yes
CDKN1C‐mutation	No	No	No

Abbreviations: w/o, without; yrs, years of age.

^a Explicit ultrasound imaging of the liver for detection of HB.